View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 6, 2016updated 13 Jul 2022 10:13am

vasopharm begins patient enrolment in NOSTRA III trial of VAS203 to treat traumatic brain injury

German biopharmaceutical company vasopharm has begun enrolling patients in its Phase III no synthase in traumatic brain injury (NOSTRA III) trial of Ronopterin (VAS203) to treat moderately to severely injured closed head traumatic brain (TBI) injury patients.

German biopharmaceutical company vasopharm has begun enrolling patients in its Phase III no synthase in traumatic brain injury (NOSTRA III) trial of Ronopterin (VAS203) to treat moderately to severely injured closed head traumatic brain (TBI) injury patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

VAS203 is an investigational nitric oxide synthase inhibitor developed as an analogue of the natural co-factor biopterin, and considered responsible for the generation of nitric oxide by the nitric oxide synthase (NOS) family of enzymes.

It causes a selective down regulation of inducible NOS (iNOS) without significantly affecting the functions of other NOS enzymes.

iNOS is considered responsible in the cascading of damaging sequellae after a traumatic brain injury.

"We believe VAS203 will provide physicians with a real opportunity to improve long-term outcomes for patients with this devastating condition."

The NOSTRA III European trial has been designed as a multicentre, randomised, double-blind, placebo-controlled study intended to test the safety and efficacy of VAS203.

It will enrol around 232 patients afflicted with moderate to severe TBI who are hospitalised and have been treated with an intra-cranial pressure probe.

During the trial, VAS203 will be administered intravenously between six and 18 hours post-injury and the infusion period will last for two days.

The secondary efficacy endpoints of the trial are to determine the quality of life (QOLIBRI) and therapy intensity level (TIL) for 14 days following the brain injury.

vasopharm CEO Christian Wandersee said: "The phase III trial is a key test to confirm our belief in the clinical efficacy of Ronopterin (VAS203) and its role in the treatment of moderately to severely injured closed head traumatic brain injury patients and leads us another step closer to bringing a drug for a highly unmet need to market.

“We believe VAS203 will provide physicians with a real opportunity to improve long-term outcomes for patients with this devastating condition."

The company is expecting the final clinical report of this study in 2019.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena